3-Methyladenine (3-MA)

For research use only.

Catalog No.S2767 Synonyms: NSC 66389

625 publications

3-Methyladenine (3-MA) Chemical Structure

CAS No. 5142-23-4

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Selleck's 3-Methyladenine (3-MA) has been cited by 625 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)		 PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 M{\TOWZ2dmO2aX;uJGF{e2G7 Mm\GNVBuVQ>? Mnv0NYg> MWXk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| NFzsfYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi2OFA{Pyd-MkG4OlQxOzd:L3G+
Jurkat MmjESpVv[3Srb36gRZN{[Xl? Mnr1NVBuVQ>? MXSxbC=> MlHP[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MkC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NkSwN|coRjJzOE[0NFM4RC:jPh?=
HeLa  MWDDfZRwfG:6aXPpeJkhSXO|YYm= NFrtVJkzdU1? M4fzWFI1cA>? NEHGUFJqdmirYnn0[ZMhfGinIHP5eI91d3irY3n0fUBw\iC|aXzpZolvcW5idH:gTIVN[SClZXzsd{4> NETjRYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi3OVM5PSd-MkG4O|U{QDV:L3G+
PC12/TetOn MlLrSpVv[3Srb36gRZN{[Xl? NID5cZkxNjFxMX3N NGjtUYEyQGh? MlrxcIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? M3zPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUC2OlU6Lz5{MUmwOlY2QTxxYU6=
RMPI8226  MX3GeY5kfGmxbjDBd5NigQ>? NUPXdGZPPW2P MVuxbC=> M{jvdpN2eHC{ZYPz[ZMhfGinIHzleoVtKG:oIHH1eI9xcGGpeTD1coRmeiCwdYTybYVvfCCmZYDs[ZRqd25? NH7s[Gs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmxOVYzOCd-MkG5NVU3OjB:L3G+
MCF-7 NVfxOWxoTnWwY4Tpc44hSXO|YYm= M4HnVlExdU1? Mof4OFhp MWPicI9kc3NiYYX0c5Bp[We7IHnu[JVk\WRiYomgZo9zfGW8b33pZi=> NWD3RXJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5N|E6OzdpPkKxPVMyQTN5PD;hQi=>
HBx  NHq3NpdCeG:ydH;zbZMhSXO|YYm= NXLOO2lROTCvTR?= NHO1O2Q1QGh? NED3VYFFVVOR MXTpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> NI[zTWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyNFA4QCd-MkKwNlAxPzh:L3G+
Marc-145 NF7Fd5BHfW6ldHnvckBCe3OjeR?= M{nZWVVuVQ>? NV3FTVR{OTJxMkSvN|Zp MoPndoVlfWOnczD0bIUhWFKUU2[geIl1\XK|IHHu[EB1cGVicILveIVqdiCneIDy[ZN{cW:w M32zc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUG5PVAxLz5{MkGxPVkxODxxYU6=
U937 MUTGeY5kfGmxbjDBd5NigQ>? MlvsNo1O MnXXNVJp M13KRYRm[3KnYYPld{B1cGViYYX0c5Bp[We7IILheIlwyqB? M4\ESVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW1NVUxLz5{MkG1OVE2ODxxYU6=
BGC-823 NGj3TGFHfW6ldHnvckBCe3OjeR?= NVfhOFkzPW2P NX3tZ2NTOmh? NHr2Z4VqdmirYnn0d{B1cGVicnH0[UBw\iCjdYTvdIhi\2mlIHPlcIx{ M{O1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{KyNVUzLz5{MkOyNlE2OjxxYU6=
A549 NXrJN41LTnWwY4Tpc44hSXO|YYm= NH\0cYExNjGvTR?= Ml33NlRp M3;HWJN2eHC{ZYPz[ZMhW1VzMUK3OE1qdmS3Y3XkJINmdGxiZHXheIg> Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2Nk[5OlAoRjJ{NE[2PVYxRC:jPh?=
pDCs NGHncolHfW6ldHnvckBCe3OjeR?= Ml20NVBuVQ>? MUewMlVp NEf2OZjDqHKnZIXj[ZMhfGinIHnu[JVkfGmxbjDv[kBKTk5vzsGgZpkhe3OUTlG0NC=> M4[zelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{m2OVk6Lz5{MkO5OlU6QTxxYU6=
HeLa  NYnhb3UxSXCxcITvd4l{KEG|c3H5 NFW3OYw2dU1? M2XSV|I1cA>? NEP3NZhqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JINmdGxiZHXheIg> Mo\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEWxNlgoRjJ{NUS1NVI5RC:jPh?=
U251  Ml\BRZBweHSxc3nzJGF{e2G7 MVy1cW0> MYKyOIg> NH\lcY1qdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq M1G2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUe5O|g5Lz5{MkW3PVc5QDxxYU6=
MCF-7  NFjWbVNCeG:ydH;zbZMhSXO|YYm= NF;EOXUxNjGvTR?= NVX4dWoyPmh? MUXlcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?= M3P4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{WxPVg6Lz5{Mke1NVk5QTxxYU6=
PC-3  MWXBdI9xfG:|aYOgRZN{[Xl? MlzINo1O NIrRXIczcA>? NI\DWmRqdmO{ZXHz[ZMhV1KLLXnu[JVk\WRiY3XscEBl\WG2aB?= NFXuPFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0OVU5OCd-MkK3OFU2QDB:L3G+
HCT116 MWPBdI9xfG:|aYOgRZN{[Xl? NWjiNVlZPW2P NVvmXXBtOjSq MkKwSG1UVw>? MX;lcohidmOnczDhdIlo\W6rbj3pcoR2[2WmIHPlcIwh\GWjdHi= NYfpVpVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlY2OjJpPkK0OlI3PTJ{PD;hQi=>
U2OS M4jPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjpfmwyOG2P M3PMU|I1cA>? MV\pcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|OUCxN{c,OjR4M{mwNVM9N2F-
A2780cp MkLFRZBweHSxc3nzJGF{e2G7 NX\4NlJDOi53bV2= MkDnNYg> NHrw[|Vl\Eh{Tx?= M3vHSIVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NHz5VVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixO|k1Pid-MkS4NVc6PDZ:L3G+
HepG2 M1;sUmZ2dmO2aX;uJGF{e2G7 NGrCW4M2dU1? MlX4OIg> MVrpcoNz\WG|ZYOgZ4VtdHWuYYKgcIV3\Wy|IH;mJGhNyqB? M{fuOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{GzOVg4Lz5{NEexN|U5PzxxYU6=
Microglia  NFjtPFZCeG:ydH;zbZMhSXO|YYm= M{XUSVVuVQ>? NH7PcIQzPGh? M3vTdYRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUi2NFEoRjJ2OEG4OlAyRC:jPh?=
MDA-MB 231 NV3pdoRsSXCxcITvd4l{KEG|c3H5 MY[1cW0> MkTINE42cA>? NVnVd4g{dW:mdXzheIV{KFSxY3;tbY7DtsLiaX7keYNm\CCjcH;weI9{cXN? NIfibHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNFc5OSd-MkS4N|A4QDF:L3G+
PANC-1  NHixSodCeG:ydH;zbZMhSXO|YYm= MUixcW0> M1rleVQ5cA>? NGrxOplFVVOR Mmr0[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> M4XmelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OESyNVU5Lz5{NEi0NlE2QDxxYU6=
MDA-MB-231 MnrSSpVv[3Srb36gRZN{[Xl? M4WzXFJuVQ>? M2DvVFQ5cA>? MWPwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg> NULScms6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5O|A3PzZpPkK0PVcxPjd4PD;hQi=>
MDA-MB-231 MYHGeY5kfGmxbjDBd5NigQ>? NVn2PHMyOm2P M1jBWlI1cA>? M1rlTIlvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= M1TXUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUewOlc3Lz5{NEm3NFY4PjxxYU6=
MCF-7  NELZRoZHfW6ldHnvckBCe3OjeR?= NEDGbWgzdU1? NUfaWVVlPDiq MYTwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg> M1PKZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUewOlc3Lz5{NEm3NFY4PjxxYU6=
MCF-7  NILS[mZHfW6ldHnvckBCe3OjeR?= M1HYfFJuVQ>? NGnZPYQzPGh? NWK4fnlLcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NInL[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3NFY4Pid-MkS5O|A3PzZ:L3G+
HepG2 MnnORZBweHSxc3nzJGF{e2G7 MnvBN41O MUm1bC=> MlX4doVlfWOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGHEdy=> NX;6eIhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|Y2QTVpPkKyPFM3PTl3PD;hQi=>
HeLa M1nURmFxd3C2b4Ppd{BCe3OjeR?= NGP4b44yOG2P MVOybC=> NXO4SGhM\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0cYVvfCC5aYToJHBGUQ>? NX\KcJNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNFAyOzVpPkKzNFAxOTN3PD;hQi=>
SK-HEP-1 M2r6ZmFxd3C2b4Ppd{BCe3OjeR?= Ml\KNVBuVQ>? M{jxO|Fp M1G5epBzd3SnY4TzJIFo[Wmwc4SgZZV1d3CqYXf5JIFv\CCrbnT1Z4V{KGGyb4D0c5NqeyCrbjDieYZidGmwLYTy[YF1\WRiY3XscJM> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3OE[0PUc,OjJ6NUi2OFk9N2F-
MDA-MB231 NFfXbW5HfW6ldHnvckBCe3OjeR?= MUK1cW0> MVyxbC=> MkfCbY5kemWjc3XzJJJme3[ncnH0do9tNW2nZHnheIVlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> MoHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyOEi4OVAoRjJ|MEi4PFUxRC:jPh?=
PaCa44 MVjBdI9xfG:|aYOgRZN{[Xl? NGK0Z2ozNjWvTR?= NVzFeZdVOWh? NITIe4Jz\WS3Y3XzxsBo\W6rcHnuMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NF3GbpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GyOFEyOid-MkOxNlQyOTJ:L3G+
T-47D MnjDSpVv[3Srb36gRZN{[Xl? NFnueHcyOG2P MUiybC=> NXnXW4NYcW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= NIjzXm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNFAzPid-MkOzNFAxOjZ:L3G+
GTL-16  NXTwTZI3SXCxcITvd4l{KEG|c3H5 MX:1cW0> MoqwNlRp NVLKfpdvemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhd{Bkd22yYYLl[EB1dyClZXzsd{B1emWjdHXkJJdqfGhiTVXUJIlvcGmkaYTvdpM> Mmf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MUO0PVAoRjJ|M{GzOFkxRC:jPh?=
U251MG  NFKzUGxHfW6ldHnvckBCe3OjeR?= Mn;EN41O MXKxbC=> MYXzeZBxemW|c3XzJGxEOy2LSTDwdo91\WmwIHX4dJJme3Orb36= MnO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|M{i2NVgoRjJ|M{O4OlE5RC:jPh?=
T24 NYnZTHQxTnWwY4Tpc44hSXO|YYm= NUXXN|M1OTCvTR?= Mor2NYg> NXXXd4Y5emWmdXPld{B1cGViY3zlZZZi\2Vib3[gUGM{KGGodHXyJIJicWOjbHnuJJRz\WG2bXXueC=> M3LDVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0NFgxLz5{M{O1OFA5ODxxYU6=
HUVECs M2n1emZ2dmO2aX;uJGF{e2G7 NFTobpk{dU1? M37ONlI1cA>? M3jPVYJtd2OtczD0bIUheHKxdHXjeIl3\SCnZn\lZ5Qhd2ZicnXzeoVz[XS{b3ygZpkhcW6qaXLpeIlv\yCjdYTvdIhi\3l? M4jBb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W4PVI5Lz5{M{O1PFkzQDxxYU6=
MCF-7  M37pOGZ2dmO2aX;uJGF{e2G7 NITHWFA2dU1? M3vrWlI1cA>? NF2wb2JqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 NUPpSpQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVU3PzlpPkKzN|k2Pjd7PD;hQi=>
Hela  NEfYbo5HfW6ldHnvckBCe3OjeR?= M2f4TlVuVQ>? NFe2bYwzPGh? M4fXeYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NYfX[G5tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVU3PzlpPkKzN|k2Pjd7PD;hQi=>
OR6 MYjGeY5kfGmxbjDBd5NigQ>? MkLuNVBuVQ>? MYe3Nog> MWTzeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{ NFrFc2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OVg4PSd-MkOzPVU5PzV:L3G+
HT-29  M4jGNGZ2dmO2aX;uJGF{e2G7 NH;G[JYydU1? MXK0PE86Pmh? M2j3XYlvcGmkaYTzJGFOWEtiaX7keYNmeyCjdYTvdIhi\2mlIHPlcIwh\GWjdHi= NXzFfGlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NFgzPzJpPkKzOVA5Ojd{PD;hQi=>
SH-SY5Y NYLCeItUS3m2b4TvfIlkcXS7IFHzd4F6 NFfDcWg2dU1? NYXj[3lwOjSq MnzPbY5kemWjc3XzJHBEViC2b4jpZ4l1gQ>? Mo\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MkWyOlUoRjJ|NUK1NlY2RC:jPh?=
Saos-2  NEDOdopCeG:ydH;zbZMhSXO|YYm= M2G0elFuVQ>? MmS1PVZp NGDnRnBqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IGDDXC=> NVnEN4k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlMyPzFpPkKzOVY{OTdzPD;hQi=>
1321N1 NEjnb3hEgXSxdH;4bYNqfHliQYPzZZk> MmPSOY1O MmD5NlRp NHf6XWZxem:2ZXP0d{Bk\WyuIHHnZYlve3RiUFPOMYlv\HWlZXSgeI95cWOrdIm= NXrHU3g4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlUzPjVpPkKzOVI2OjZ3PD;hQi=>
A2780 M{jPWGFxd3C2b4Ppd{BCe3OjeR?= M1XCSlVuVQ>? NUPScWxvOjSq MnLnZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? NVTLbItWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVIzQDFpPkKzOVkzOjhzPD;hQi=>
OV2008 MljTRZBweHSxc3nzJGF{e2G7 NVzHRnZ5PW2P NXr0UlEyOjSq NIW0[GZkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= M{DkPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUmyNlgyLz5{M{W5NlI5OTxxYU6=
PC12  MkPJSpVv[3Srb36gRZN{[Xl? NUDLPZFCOTCvTR?= M1m4b|I1cA>? NETNd2x4[XSnch?= MnW3xsBqdmirYnn0d{BkcHmvb4TyfZB{cW5vbHnr[UBxem:2ZXHzc41idCCjY4Tpeol1gS5? MnnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEO5O|koRjJ|NkCzPVc6RC:jPh?=
SH-SY5Y M4\NOmFxd3C2b4Ppd{BCe3OjeR?= MV61cW0> NXLGTYt7OWh? MWjhZo9tcXOqZYOgZ4Vt[XO2cn;sJI5mfXKxcILveIVkfGm4ZTDl[oZm[3R? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOUO5OUc,OjN4MUmzPVU9N2F-
SH-SY5Y NELLfVlHfW6ldHnvckBCe3OjeR?= NFP2V|EydU1? M2LHW|I1cA>? MXHpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2M{G0PEc,OjN5NEOxOFg9N2F-
HepG2 MXrGeY5kfGmxbjDBd5NigQ>? NILkdHEyOG2P NGXJNYczPGh? MoPlbY5pcWKrdIOgd4lVUUeDUj2gZY5lKEiEU2OtbY5lfWOnZDDheZRweGijZ4m= Mn;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MUewOFAoRjJ|OEG3NFQxRC:jPh?=
HeLa Ml7xSpVv[3Srb36gRZN{[Xl? MoHDNVBuVQ>? MoHrNog> MnXDd5VxeHKnc4Pld{BNSzNiSVmg[ZhxemW|c3nzc44> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh4NEezPEc,OjN6NkS3N|g9N2F-
HONE-1  MlPLSpVv[3Srb36gRZN{[Xl? MnPrOY1O NXz1PXpkOWh? MnXZdoVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh7MkO1PEc,OjN6OUKzOVg9N2F-
MCF7 MoDDSpVv[3Srb36gRZN{[Xl? NI\qWYc2dU1? NFXNbYQzPGh? NVLab3A6cW6lcnXhd4V{KEO3TzDpcoR2[2WmIHPlcIwh\GWjdHi= NH7wUGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlYzQSd-MkO5OlI3Ojl:L3G+
HO8910 NXLDNHZkSXCxcITvd4l{KEG|c3H5 NWDpXmh3OTCvTR?= MoTRNVJp Mo\t[Y5p[W6lZYOgRlE6NWmwZIXj[YQh[XCxcITvd4k> M1naNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUizOlExLz5{M{m4N|YyODxxYU6=
SMMC-7721 MVrBdI9xfG:|aYOgRZN{[Xl? MV61cW0> Mnu3NlRp MmjvZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz MlrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNk[2PVMoRjJ2ME[2Olk{RC:jPh?=
Hep3B NFnwTHFCeG:ydH;zbZMhSXO|YYm= MWC1cW0> NYK3UZhtOjSq NXLQ[o1F[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ MmDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNk[2PVMoRjJ2ME[2Olk{RC:jPh?=
H460 NU\YRpV[TnWwY4Tpc44hSXO|YYm= M{\hflExdU1? NEDDbXM1cA>? NF7Cd4RqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NVP3W2ZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|MzODhpPkK0NVc{OjB6PD;hQi=>
A549 M1ewN2Z2dmO2aX;uJGF{e2G7 MXmxNI1O MYm0bC=> MX;pcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBqenKjZHnheIlwdg>? NUXub3BORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFI4OzVpPkK0NVQzPzN3PD;hQi=>
H1299  NFXlVpVHfW6ldHnvckBCe3OjeR?= NVy4WYZ[OTCvTR?= MmW3OIg> NULvS|FZcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5M{KwPEc,OjRzN{OyNFg9N2F-
WiDr NV;BcJJtTnWwY4Tpc44hSXO|YYm= NEjXToUyOG2P MonJNYg> MkDBbY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v NGixU5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG5NFQ5QSd-MkSxPVA1QDl:L3G+
LoVo  MV7BdI9xfG:|aYOgRZN{[Xl? NXyzXXUzPW2P MWi0PIg> NG\5[XJmdmijbnPld{BFS0FvaX7keYNm\CCjcH;weI9{cXNw MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyMUixNkc,OjR{MEG4NVI9N2F-
HepG2 E47 MYXGeY5kfGmxbjDBd5NigQ>? NEHocVkzNjWvTR?= NF\FU2I1QGh? NXXxfFF7cW6lcnXhd4V{KHSqZTD0c5hq[2m2eTDv[kBCSSxiQmPPMEBidmRiQ1PsOC=> NX7yZ205RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M4OzhpPkK0Nlc{PzN6PD;hQi=>
RKO MkizSpVv[3Srb36gRZN{[Xl? M{T4PVJuVQ>? NXPDc2NnOWh? MX;EUXNQ M2PQfIVvcGGwY3XzJINmdGxiZHXheIgh[nliZ3Xs[IFv[W27Y3nu MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7MUe3O{c,OjR{OUG3O|c9N2F-
Hep3B M1O4[2Fxd3C2b4Ppd{BCe3OjeR?= MYKycW0> MUCxNog> MXfEUXNQ MnHFbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= M1vYbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3N|AxLz5{NEK5O|MxODxxYU6=
ACHN-5968 MVfBdI9xfG:|aYOgRZN{[Xl? NILkdG82dU1? MWSzbC=> M4nJRYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MEW2NFQoRjJ2M{C1OlA1RC:jPh?=
Huh7 NEnUepJCeG:ydH;zbZMhSXO|YYm= MlHINo1O MYWxNog> MYHEUXNQ NWjBWoVCcW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg> NVTBc4VpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc{ODBpPkK0Nlk4OzByPD;hQi=>
UOK257 NHvNU2VCeG:ydH;zbZMhSXO|YYm= NYrIZpJLPW2P M{PYbVNp NXPLOpVU\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNyNU[wOEc,OjR|MEW2NFQ9N2F-
ECSCs  NG\MOoVCeG:ydH;zbZMhSXO|YYm= NUPPfFdQOTCvTR?= NV\EZnAxPGh? M1foT4Rm[3KnYYPld{Bz[XCjbYnjbY4ufHKnYYTl[EBieG:ydH;zbZM> NXTSNoJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVkyODlpPkK0N|E6OTB7PD;hQi=>
MCF-7  MlTWSpVv[3Srb36gRZN{[Xl? MV[xNI1O NVzCcVk2OjSq M3XWWYlvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= NHLobGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOxOVU4QCd-MkSzNVU2Pzh:L3G+
SGC-7901  MlfMRZBweHSxc3nzJGF{e2G7 NGnZXFQzdU1? NFSyPGEycA>? NWLZcVY5cW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NXr5RZJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlE{PDBpPkK0N|IyOzRyPD;hQi=>
SMMC-7721 M3XrOWFxd3C2b4Ppd{BCe3OjeR?= NHe2dZkzdU1? MYOxbC=> M{LpNIlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| MofPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkGzOFAoRjJ2M{KxN|QxRC:jPh?=
T24 MnvVRZBweHSxc3nzJGF{e2G7 M{DrOlVuVQ>? MVmxMlVp M4ewPJBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? NGr6emY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0PVE4Pid-MkSzOFkyPzZ:L3G+
NTUB1 M1;IVmFxd3C2b4Ppd{BCe3OjeR?= NF\6XXI2dU1? NFG5fFUyNjWq MonkdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NFXUVJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0PVE4Pid-MkSzOFkyPzZ:L3G+
MG-63 NIm1U5hCeG:ydH;zbZMhSXO|YYm= NVWzPXJJOTCvTR?= MoS3NVJp NXjwXo5F\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OEOwNUc,OjR|NUizNFE9N2F-
MG-63 MkXERZBweHSxc3nzJGF{e2G7 NFTGc2wxNjVxMX3N MonoN|Jp MljS[Y5p[W6lZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?= NUHkZmNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVg{PDJpPkK0N|U5OzR{PD;hQi=>
MG-63 MV;GeY5kfGmxbjDBd5NigQ>? MV[wMlUwOW2P NWDxfopwPDiq NYqy[FB[cW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? M3vEe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W4N|QzLz5{NEO1PFM1OjxxYU6=
U2OS  MY\GeY5kfGmxbjDBd5NigQ>? MUCwMlUwOW2P NV7LSVB[PDiq MVjpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OEO0Nkc,OjR|NUizOFI9N2F-
HGC-27 MmDYSpVv[3Srb36gRZN{[Xl? MUCxNI1O NUDYSYV[OWh? MULpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgcI9{eyCkeTDSRWQxODFib4KgUWsuOjJyNh?= MknhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MU[zOFkoRjJ2NEG2N|Q6RC:jPh?=
HCT116  NGS4TWNCeG:ydH;zbZMhSXO|YYm= NXTRNoVCPW2P NWfzPJhlOjSq NH7RNIxmdmijbnPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZZBq\2WwaX6= NFmyUJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yOlUzOid-MkS2NlY2OjJ:L3G+
A549 NH7YOmdCeG:ydH;zbZMhSXO|YYm= Mof5NVBuVQ>? MWe0PIg> MVLhZ4NmdGW{YYTld{B1cGVicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgVHRZ MoLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4Mk[3NlIoRjJ2NkK2O|IzRC:jPh?=
Saos-2 M4\nNGFxd3C2b4Ppd{BCe3OjeR?= NUjFZotJOTCvTR?= MkLFNlRp NIjuN3ZqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|OUCxN{c,OjR4M{mwNVM9N2F-
U2OS MXnBdI9xfG:|aYOgRZN{[Xl? M{PKV|ExdU1? NH\HZ5UzPGh? Ml7mbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|OUCxN{c,OjR4M{mwNVM9N2F-
HepG2 MmLvSpVv[3Srb36gRZN{[Xl? MlzTOY1O Ml;mOIg> MkXDbY5kemWjc3XzJGhNKHKnbHXhd4U> MoPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MUO1PFcoRjJ2N{GzOVg4RC:jPh?=
A549 NEDDdXdCeG:ydH;zbZMhSXO|YYm= M{PiTVVuVQ>? NEPTXJU1QGh? MnTV[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGxiZHXheIgh[W6mIHX4dJJme3Orb36gcIV3\Wy|IH;mJINie3Cjc3WtN{whSmWlbHnuMVEh[W6mIFzDN{1KUQ>? MorOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5ME[zNFMoRjJ2N{C2N|A{RC:jPh?=
A2780cp NFTCTWtCeG:ydH;zbZMhSXO|YYm= NInIXo0zNjWvTR?= MUixbC=> M3K4[oRlUDKR Ml6w[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NEfs[oo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixO|k1Pid-MkS4NVc6PDZ:L3G+
Microglia  M2PTe2Fxd3C2b4Ppd{BCe3OjeR?= MUe1cW0> MXuyOIg> Mlzr[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo NUO3N|E4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVg3ODFpPkK0PFE5PjBzPD;hQi=>
HT-29  NIP6To9CeG:ydH;zbZMhSXO|YYm= MoTYNY1O M4i0cFQ5cA>? MnrISG1UVw>? M1v2ZYVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NGTuS3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi0NlE2QCd-MkS4OFIyPTh:L3G+
MDR M2CyemFxd3C2b4Ppd{BCe3OjeR?= M17uUFExdU1? M1m4[VZp MmjZd5Rz\W6pdHjlcpMhfGinIIDve4VzKG:oIHHueIlk[W6lZYKg[JJ2\3N? NIHWW3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxPVcxOSd-MkWwNVk4ODF:L3G+
H157 M1PhWGZ2dmO2aX;uJGF{e2G7 NETOXI82dU1? MnKwNog> NVnTRZp4e3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ6NU[yPEc,OjV{OEW2Nlg9N2F-
A549  NWS0fot{TnWwY4Tpc44hSXO|YYm= NH\Vc5A2dU1? MkX5Nog> MXjzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ6NU[yPEc,OjV{OEW2Nlg9N2F-
A2780cp  MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLCfIQydU1? NGT5RoMycA>? M1LrW4lv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NE\pe5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOyNlY6PCd-MkWzNlI3QTR:L3G+
NBL-W-S  NXX3e|F4SXCxcITvd4l{KEG|c3H5 M2DrcFFuVQ>? NUG1SlVpPmh? NUjrW2tscW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhT0GQVD22NS=> Mo\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MkOyNlIoRjJ3M{KzNlIzRC:jPh?=
NBL-W-S  NIrvT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fXU|FuVQ>? MojnOog> Mn7t[Y5p[W6lZYOgS2FPXC14MTD0c5hq[2m2eR?= NFj1VFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOyN|IzOid-MkWzNlMzOjJ:L3G+
A549  Mn\ZRZBweHSxc3nzJGF{e2G7 NUXiOGp{PW2P MkT2Nog> Mn\uSG1UVw>? NYTRW4RkcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNkW2NUc,OjV5MU[1OlE9N2F-
95D MoLnRZBweHSxc3nzJGF{e2G7 NWfiVVlDPW2P MUOybC=> MmnKSG1UVw>? NVvVW4VjcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo NX24PVBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVY2PjFpPkK1O|E3PTZzPD;hQi=>
A549  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32x[FNuVQ>? MWSybC=> M4Hy[2ROW09? M4fpdZJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? NX36[I92RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVY2PjFpPkK1O|E3PTZzPD;hQi=>
95D NISzR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOzcW0> M3ns[FJp M4rzXWROW09? NGLSPZRz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F NEHueGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOlU3OSd-MkW3NVY2PjF:L3G+
Nara-H MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvBOY1O MWS0PIg> NWj5dIlG\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> Mm\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEWwN|MoRjJzOEC1NFM{RC:jPh?=
HUVECs M4C0dWZ2dmO2aX;uJGF{e2G7 Mn[5NVBuVQ>? M{PUXFAvPWh? MoTK[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= NUjVc|lkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0Olg2QTJpPkKxOFY5PTl{PD;hQi=>
HepG2 NYHzeXJ5SXCxcITvd4l{KEG|c3H5 NVnXcYNlOm2P MkXINYg> M3;DVYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxiZHXheIg> MoPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NUO2PVEoRjJzNEWzOlkyRC:jPh?=
U-2 OS MlztdWhVWyCjc4PhfS=> Mo\1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?= NULWfYg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MWnxTHRUKGG|c3H5 MmrVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MmTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY MkfkdWhVWyCjc4PhfS=> NVrsd4RPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= NH3WPIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MXfxTHRUKGG|c3H5 MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NX;mOmhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 NUfZeo9{eUiWUzDhd5NigQ>? MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NIn5cGdyUFSVIHHzd4F6 M3XNW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MojEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NXzWTYg4eUiWUzDhd5NigQ>? NGrUeZFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> NEH5WnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 M4r1U5FJXFNiYYPzZZk> MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? Mom1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) Mo\TdWhVWyCjc4PhfS=> M3\jcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 MoXadWhVWyCjc4PhfS=> NUXFcHVVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> MoP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MVrxTHRUKGG|c3H5 MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 NGfwcY1yUFSVIHHzd4F6 NGDkepZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= NFGxcoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 NVq5U3dZeUiWUzDhd5NigQ>? Ml3tdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NV;jXGpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 M1u0PZFJXFNiYYPzZZk> M3rKd5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NFfk[pVyUFSVIHHzd4F6 NEL2bnNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 MlLhdWhVWyCjc4PhfS=> NH3ZTWlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> NUn3fmt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NGfvO2lyUFSVIHHzd4F6 MlfKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| MkGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 NGDG[pByUFSVIHHzd4F6 NW\sVJhreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5
CAS No. 5142-23-4
Storage 3 years -20°C powder
Synonyms NSC 66389
Smiles CN1C=NC(=N)C2=C1N=CN2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

selleck catalog

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147) New

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • LY294002

    LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

  • Wortmannin (KY 12420)

    Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

  • Dactolisib (BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

  • Buparlisib (BKM120)

    Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID